

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
OAKLAND DIVISION**

JONNIE HOMYK, et al.,

Plaintiffs,

v.

CHEMOCENTRYX, INC. et al.,

Defendants.

Master File No. 4:21-cv-03343-JST *and
related case*, No. 4:21-cv-04357

**NOTICE OF (I) PROPOSED CLASS ACTION
SETTLEMENT; (II) SETTLEMENT HEARING; AND
(III) MOTION FOR ATTORNEYS' FEES AND LITIGATION EXPENSES**

TO: All persons who purchased or otherwise acquired the common stock of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") from November 26, 2019 through May 6, 2021, inclusive (the "Class Period"), and were damaged thereby.

A Federal Court authorized this Settlement Notice.

This is not a solicitation from a lawyer.

NOTICE OF SETTLEMENT: Please be advised that Class Representative Indiana Public Retirement System ("Class Representative" or "Lead Plaintiff"), on behalf of itself and the Class (as defined in ¶ 28 below), has reached a proposed settlement of the Action for **\$69,000,000** in cash that, if approved, will resolve all claims in the Action (the "Settlement").

PLEASE READ THIS NOTICE CAREFULLY. This Notice explains important rights you may have, including the possible receipt of cash from the Settlement. If you are a member of the Class, your legal rights will be affected whether or not you act.

If you have any questions about this Notice, the proposed Settlement, or your eligibility to participate in the Settlement, please **DO NOT** contact the Court, the Office of the Clerk of the Court, ChemoCentryx, any other Defendants in the Action, or their counsel. All questions should be directed to Class Counsel or the Claims Administrator (*see* ¶ 78 below).¹

1. **Description of the Action and the Class:** This Notice relates to a proposed Settlement of claims in a pending securities class action brought by investors alleging that ChemoCentryx and its former President and Chief Executive Officer, Dr. Thomas J. Schall (together, "Defendants"), violated the federal securities laws by making material misrepresentations during the Class Period regarding ChemoCentryx's ADVOCATE study, the Company's Phase 3 clinical trial of its vasculitis drug avacopan, and concerning the Company's communications with the FDA related to the approval of avacopan. Defendants deny all allegations in the Action and deny any violations of the federal securities law. A more detailed description of the Action is set forth in paragraphs 10-27 below. If the Court approves the proposed Settlement, the Action will be dismissed and members of the Class (defined in paragraph 28 below) will settle and release all Released Plaintiff's Claims (defined in paragraph 37 below).

¹ All capitalized terms used in this Notice that are not otherwise defined herein shall have the meanings set forth in the Revised Stipulation and Agreement of Settlement dated May 15, 2026 (the "Stipulation"), which is available at www.ChemoCentryxSecuritiesLitigation.com.

2. **Statement of the Class's Recovery:** Subject to Court approval, Class Representative, on behalf of itself and the Class, has agreed to settle the Action in exchange for a settlement payment of **\$69,000,000** in cash (the "Settlement Amount") to be deposited into an escrow account. The Net Settlement Fund (*i.e.*, the Settlement Amount plus any and all interest earned thereon (the "Settlement Fund") less (a) any Taxes, (b) any reasonable Notice and Administration Costs, (c) any Litigation Expenses awarded by the Court, (d) any attorneys' fees awarded by the Court; and (e) any other costs or fees approved by the Court) will be distributed in accordance with a plan of allocation that is approved by the Court, which will determine how the Net Settlement Fund shall be allocated among members of the Class. The proposed plan of allocation (the "Plan of Allocation") is attached hereto as Appendix A.

3. **Estimate of Average Amount of Recovery Per Share:** Based on Class Representative's damages expert's estimate of the number of ChemoCentryx common stock shares that may have been affected by the misstatements alleged in the Action and assuming that all Class Members elect to participate in the Settlement, the estimated average recovery (before the deduction of any Court-approved fees, expenses, and costs as described herein) is \$2.88 per eligible share of ChemoCentryx common stock. **Class Members should note, however, that the foregoing average recovery per share is only an estimate.** Some Class Members may recover more or less than this estimated amount depending on, among other factors, when and at what prices they purchased or sold their ChemoCentryx common stock, and the total number and value of valid Claim Forms submitted. Distributions to Class Members will be made based on the Plan of Allocation set forth in Appendix A or such other plan of allocation as may be ordered by the Court.

4. **Average Amount of Damages Per Share:** The Parties disagree about both liability and damages and do not agree on the average amount of damages per share that would be recoverable if Class Representative were to prevail in the Action. Among other things, Defendants do not agree with the assertion that they violated the federal securities laws or that any damages were suffered by any Class Members as a result of their conduct.

5. **Attorneys' Fees and Expenses Sought:** Court-appointed Class Counsel, Bernstein Litowitz Berger & Grossmann LLP, which has been prosecuting the Action on a wholly contingent basis for more than four years, has not received any payment of attorneys' fees for its representation of the Class and has advanced the funds to pay expenses necessarily incurred to prosecute this Action. Class Counsel will apply to the Court for an award of attorneys' fees in an amount not to exceed 22% of the Settlement Fund. In addition, Class Counsel will apply for payment of the Litigation Expenses incurred in connection with the institution, prosecution, and resolution of the Action, in an amount not to exceed \$5 million. Any fees and expenses awarded by the Court will be paid from the Settlement Fund. Class Members are not personally liable for any such fees or expenses. If the Court approves Class Counsel's fee and expense application, the estimated average cost will be \$0.84 per affected share of ChemoCentryx common stock.

6. **Identification of Attorneys' Representatives:** Class Representative and the Class are represented by Jonathan D. Uslander of Bernstein Litowitz Berger & Grossmann LLP, 2121 Avenue of the Stars, Suite 2575, Los Angeles, CA 90067, 1-800-380-8496, settlements@blbglaw.com. Further information regarding the Action, the Settlement, and this Settlement Notice may be obtained by contacting the Claims Administrator at: *ChemoCentryx Securities Litigation*, c/o Kroll Settlement Administration, P.O. Box 5013, New York, NY 10150-5013; info@ChemoCentryxSecuritiesLitigation.com; (833) 522-2606; or by visiting the case website, www.ChemoCentryxSecuritiesLitigation.com.

7. **Reasons for the Settlement:** Class Representative’s principal reason for entering into the Settlement is the near-term cash benefit for the Class without the substantial risks and the delays inherent in further litigation. The substantial cash benefit provided under the Settlement must be considered against the significant risk that no recovery at all might be obtained. At the time the Settlement was reached, the Action had been dismissed in its entirety on Defendants’ motion for summary judgment, and any recovery for the Class was dependent on the resolution of the pending appeal in favor of Class Representative, and the potential outcome at trial (if the appeal succeeded). Moreover, any recovery obtained for the Class through litigation could not be expected for at least several years. Defendants, who deny all allegations of wrongdoing or liability whatsoever, are entering into the Settlement solely to eliminate the uncertainty, burden, and expense of further protracted litigation.

YOUR LEGAL RIGHTS AND OPTIONS IN THE SETTLEMENT:	
SUBMIT A CLAIM FORM POSTMARKED OR SUBMITTED ONLINE NO LATER THAN OCTOBER 1, 2026.	This is the only way to be eligible to receive a payment from the Settlement Fund. If you are a Class Member, you will be bound by the Settlement as approved by the Court and you will give up any Released Plaintiff’s Claims (defined in ¶ 37 below) that you have against Defendants and the other Defendants’ Releasees (defined in ¶ 38 below), so it is in your interest to submit a Claim Form.
OBJECT TO THE SETTLEMENT BY SUBMITTING A WRITTEN OBJECTION SO THAT IT IS POSTMARKED OR FILED NO LATER THAN SEPTEMBER 21, 2026.	If you do not like the proposed Settlement, the proposed Plan of Allocation, or the request for attorneys’ fees and Litigation Expenses, you may write to the Court and explain why you do not like them. You cannot object to the Settlement, the Plan of Allocation, or the fee and expense request unless you are a Class Member.
GO TO A HEARING ON OCTOBER 22, 2026 AT 2:00 P.M. PACIFIC TIME, AND FILE A NOTICE OF INTENTION TO APPEAR SO THAT IT IS RECEIVED NO LATER THAN SEPTEMBER 21, 2026.	Filing a written objection and notice of intention to appear by September 21, 2026 allows you to speak in Court, at the discretion of the Court, about the fairness of the proposed Settlement, the Plan of Allocation, and/or the request for attorneys’ fees and Litigation Expenses. If you submit a written objection, you may (but you do not have to) attend the hearing and, at the discretion of the Court, speak to the Court about your objection. If you do not submit a written objection, you are unlikely to be allowed to speak in Court about the fairness of the settlement.
DO NOTHING.	If you are a member of the Class and you do not submit a valid Claim Form, you will not be eligible to receive any payment from the Settlement Fund. You will, however, remain a member of the Class, which means that you give up your right to sue about the claims that are resolved by the Settlement and you will be bound by any judgments or orders entered by the Court in the Action.

These rights and options—and the deadlines to exercise them—are further explained in this Notice. Please Note: the date and time of the Settlement Hearing—currently scheduled for October 22, 2026 at 2:00 p.m. Pacific Time by Zoom videoconference—is subject to change without further notice to the Class. If you plan to attend the hearing, you should check the case website, www.ChemoCentryxSecuritiesLitigation.com, or with Class Counsel as set forth above, to obtain information about how to access the Settlement Hearing and to confirm that no change to the date or time of the hearing has been made.

WHAT THIS NOTICE CONTAINS

Why Did I Get This Settlement Notice?	Page 4
What Is This Case About?	Page 4
How Do I Know If I Am Affected By The Settlement?	Page 6
Who Is Included In The Class?	
What Are Class Representative's Reasons For The Settlement?	Page 7
What Might Happen If There Were No Settlement?	Page 8
How Are Class Members Affected By The Action And The Settlement?	Page 8
How Do I Participate In The Settlement? What Do I Need To Do?	Page 10
How Much Will My Payment Be?	Page 10
What Payment Are The Attorneys For The Class Seeking?	Page 12
How Will The Lawyers Be Paid?	
What If I Previously Requested Exclusion From The Class And Now Want To Be Eligible To Receive A Payment From The Settlement?	Page 12
How Do I Opt Back Into The Class	
When And Where Will The Court Decide Whether To Approve The Settlement?	Page 12
Do I Have To Come To The Hearing? May I Speak At The Hearing If I Don't Like The Settlement?	
What If I Bought ChemoCentryx Common Stock On Someone Else's Behalf?	Page 14
Can I See The Court File? Whom Should I Contact If I Have Questions?	Page 15
Appendix A: Plan of Allocation of the Net Settlement Fund	Page 16

WHY DID I GET THIS SETTLEMENT NOTICE?

8. The purpose of this Settlement Notice is to inform potential Class Members of the terms of the proposed Settlement, and of a hearing to be held by the Court to consider the fairness, reasonableness, and adequacy of the Settlement, the proposed Plan of Allocation, and the motion by Class Counsel for attorneys' fees and Litigation Expenses (the "Settlement Hearing"). See ¶¶ 62-63 below for details about the Settlement Hearing, including the date and time of the hearing.

9. The issuance of this Settlement Notice is not an expression of any opinion by the Court concerning the merits of any claim in the Action, and the Court still has to decide whether to approve the Settlement. If the Court approves the Settlement and a plan of allocation, then payments to Authorized Claimants will be made after any appeals are resolved and after the completion of all claims processing. Please be patient, as this process can take some time to complete.

WHAT IS THIS CASE ABOUT?

10. ChemoCentryx is a biopharmaceutical company incorporated under the laws of the State of Delaware, with its corporate headquarters and principal place of business in California. Until October 19, 2022, ChemoCentryx's common stock traded on the NASDAQ stock exchange under the ticker symbol "CCXI." In the Action, Class Representative alleged that Defendants made misstatements to investors during the Class Period about the safety and efficacy of ChemoCentryx's vasculitis drug called avacopan, and the Company's application for FDA approval of avacopan.

11. The initial complaint in this action was filed on May 5, 2021. On January 28, 2022, the Honorable Jon S. Tigar appointed Indiana Public Retirement System as Lead Plaintiff and Bernstein Litowitz Berger & Grossmann LLP as Lead Counsel for the potential Class.

12. On March 28, 2022, Lead Plaintiff filed the Amended Consolidated Class Action Complaint for Violations of Federal Securities Laws (the “Complaint”). In the Complaint, Lead Plaintiff alleged that Defendants ChemoCentryx and Schall violated Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Securities and Exchange Commission Rule 10b-5, by making alleged misrepresentations concerning ChemoCentryx’s ADVOCATE study, the Company’s Phase 3 clinical trial of avacopan, and the Company’s communications with the FDA related to the approval of avacopan. Lead Plaintiff alleged that these misstatements and omissions caused the price of ChemoCentryx common stock to be artificially inflated during the Class Period and caused damages to investors when the market later allegedly learned the truth allegedly concealed by Defendants’ misleading statements. Lead Plaintiff further alleged claims under Sections 20(a) and 20A of the Exchange Act against Defendant Schall, alleging that Schall controlled ChemoCentryx when the Company made the alleged misstatements concerning avacopan in violation of Section 20(a); and that Schall sold ChemoCentryx stock while in possession of material non-public information about avacopan, and that Lead Plaintiff and other Class Members purchased ChemoCentryx stock contemporaneously with those sales, in violation of Section 20A.

13. Defendants moved to dismiss the Complaint on May 19, 2022. On February 23, 2023, the Court issued an order granting in part and denying in part Defendants’ motion to dismiss. Defendants filed their Answer to the Complaint on April 27, 2023.

14. On August 25, 2023, Lead Plaintiff filed a motion for class certification. After full briefing and a hearing, on March 6, 2024, Judge Tigar issued an Order granting the motion and certifying the Class as defined in ¶ 28 below, appointing Lead Plaintiff as Class Representative for the Class, and appointing Lead Counsel as Class Counsel. On May 23, 2024, the United States Court of Appeals for the Ninth Circuit denied Defendants’ petition for leave to take an immediate appeal of the Court’s order certifying the Class pursuant to Rule 23(f) of the Federal Rules of Civil Procedure.

15. The Parties conducted a private mediation in February 2024. No settlement was reached at that time.

16. On September 25, 2024, Class Representative filed an unopposed motion for Court approval of the Parties’ agreed form and manner of providing notice to the Class of pendency of the class action. On October 17, 2024, the Court entered an Order granting that motion (the “Class Notice Order”).

17. Pursuant to the Class Notice Order, the Class Notice provided Class Members with the opportunity to request exclusion from the Class, explained that right, and set forth the deadline and procedures for doing so. The Class Notice informed Class Members that if they chose to remain a member of the Class, they would “be legally bound by all determinations, orders, and judgments that the Court makes in the Action, whether favorable or unfavorable.”

18. The Class Notice was mailed to 35,220 potential Class Members beginning on November 13, 2024. The deadline for requesting exclusion from the Class pursuant to the Class Notice was January 14, 2025. A list of the persons and entities who requested exclusion from the Class pursuant to the Class Notice is available at www.ChemoCentryxSecuritiesLitigation.com.

19. During discovery, Defendants produced approximately 7.8 million pages of documents and dozens of third parties (including the FDA, Amgen, and ChemoCentryx’s consultants, bankers, and former employees) produced tens of thousands of additional pages of documents. The Parties conducted 21 depositions of fact witnesses and 17 depositions of expert witnesses; and prepared and exchanged 24 expert reports.

20. On February 13, 2025, Class Representative and Defendants filed a total of 11 motions to exclude portions of expert testimony offered by the adverse party. The Court heard oral argument on April 10, 2025 and decided those motions on May 21, 2025.

21. Class Representative filed a motion for partial summary judgment on May 8, 2025, and Defendants filed a motion for summary judgment on May 29, 2025. The Court heard oral argument on those motions on August 7, 2025.

22. On August 15, 2025, the Court issued an Order granting Defendants' motion for summary judgment and denying Class Representative's motion as moot. On the same day, the Court issued its Judgment.

23. On September 12, 2025, Class Representative appealed the Court's Order Granting Defendants' Motion for Summary Judgment and the Judgment to the Ninth Circuit Court of Appeals. On January 5, 2026, Class Representative filed its opening brief in support of its appeal.

24. On January 26, 2026, while Class Representative's appeal was pending, the Parties executed a Memorandum of Understanding ("MOU") reflecting an agreement in principle to settle all claims in this Action against Defendants and Defendants' Releasees (defined below) in return for a cash payment of \$35,000,000 for the benefit of the Class, subject to the execution of a customary "long form" stipulation and agreement of settlement and related papers.

25. The Parties entered into a Settlement and Agreement of Settlement dated March 9, 2026 (the "Original Settlement Stipulation") setting forth the terms and conditions of the proposed \$35,000,000 settlement (the "Original Settlement"), and on March 13, 2026, Class Representative filed a motion for preliminary approval of the Original Settlement.

26. On April 27, 2026, after the filing of Class Representative's motion for preliminary approval of the Original Settlement, the Center for Drug Evaluation and Research ("CDER") of the Food and Drug Administration ("FDA") filed a public notice proposing the withdrawal of TAVNEOS (avacopan). Following CDER's announcement, the Parties engaged in further negotiations culminating in a revised agreement to settle all claims in this Action against Defendants and Defendants' Releasees in return for a cash payment of \$69,000,000 for the benefit of the Class. On May 15, 2026, the Parties entered into the Revised Stipulation and Agreement of Settlement (the "Stipulation"), which sets forth the full terms and conditions of the \$69,000,000 Settlement and supersedes and voids the Original Settlement Stipulation and the Original Settlement. The Stipulation can be viewed at www.ChemoCentryxSecuritiesLitigation.com.

27. On June 12, 2026, the Court preliminarily approved the Settlement, authorized notice of the Settlement to be disseminated to potential Class Members, and scheduled the Settlement Hearing to consider whether to grant final approval to the Settlement.

**HOW DO I KNOW IF I AM AFFECTED BY THE SETTLEMENT?
WHO IS INCLUDED IN THE CLASS?**

28. If you are a member of the Class, you are subject to the Settlement, unless you previously requested to be excluded from the Class. The Class was certified by the Court's Order dated March 6, 2024 and consists of:

all persons who purchased or otherwise acquired the common stock of ChemoCentryx between November 26, 2019 and May 6, 2021, inclusive, and were damaged thereby

Excluded from the Class are: (a) Defendants; (b) their respective successors and assigns; (c) the past and current executive officers and directors of Defendants; (d) the Immediate Family Members of Defendant Thomas J. Schall; and (e) the legal representatives, heirs, successors, or assigns of any excluded person, and any entity in which any of the above excluded persons have or had a direct or controlling ownership interest, and the legal representatives, heirs, successors-in-interest or assigns of any such excluded persons or entities. Also excluded from the Class are persons and entities who excluded themselves from the Class pursuant to the Class Notice (a list of the persons and entities who requested exclusion is available at www.ChemoCentryxSecuritiesLitigation.com). However, those persons or entities may choose to participate in the Settlement by following the instructions in ¶ 59 below.

Please Note: Receipt of this Notice does not mean that you are a Class Member or that you will be entitled to receive proceeds from the Settlement.

If you are a Class Member and you wish to be eligible to participate in the distribution of proceeds from the Settlement, you are required to submit a Claim Form and the required supporting documentation as set forth therein postmarked (or submitted online) no later than October 1, 2026. The Claim Form is available at www.ChemoCentryxSecuritiesLitigation.com, and an online claim can be submitted through that website.

WHAT ARE CLASS REPRESENTATIVE'S REASONS FOR THE SETTLEMENT?

29. At the time the Settlement was reached, all claims asserted by Class Representative had been dismissed by the District Court when it entered its Order granting Defendants' motion for summary judgment. The Court found that all of Class Representative's alleged misrepresentations were inactionable either because they were statements of opinion or were not misleading. Therefore, any recovery for the Class through litigation could only be obtained if (a) Class Representative obtained a reversal of the Court's order granting Defendants' motion for summary judgment through its pending appeal, and (b) thereafter succeeded at trial on remand. There were very significant risks presented by the current appeal that could have led to no recovery at all, and—even if Class Representative had succeeded on appeal and proceeded to trial—it would have faced a number of substantial arguments regarding liability and damages from Defendants.

30. First, there was a significant risk that Class Representative might not prevail on its pending appeal. While Class Representative believed that it had meritorious arguments for reversal, there was a substantial risk that the Court of Appeals might affirm the District Court's order granting summary judgment. Moreover, even if Class Representative prevailed on the appeal, the District Court could still potentially grant summary judgment again to Defendants on other grounds that the Court did not reach the first time. Finally, even if Class Representative was able to bring its claims to trial, it would still face significant challenges at trial in proving that the alleged misstatements were false and misleading and in proving damages.

31. In light of these and other risks, the amount of the Settlement, and the immediacy of recovery to the Class, Class Representative and Class Counsel believe that the proposed Settlement is fair, reasonable, and adequate, and in the best interests of the Class. The Settlement provides a substantial benefit to the Class, namely \$69,000,000 in cash (less the various deductions described in this Notice), as compared to the risk that the claims in the Action would produce a smaller recovery, or no recovery at all, after further pretrial proceedings, at trial, and on any appeals, possibly years in the future.

32. Defendants expressly deny that Class Representative has asserted any valid claims as to any of them, and expressly deny any and all allegations of fault, liability, or wrongdoing whatsoever. Defendants further deny that Class Members were harmed or suffered any damages as a result of the conduct alleged in the Action. Defendants have agreed to the Settlement solely to eliminate the risks, burdens, and expense of continued litigation. Accordingly, the Settlement may not be construed as an admission of any wrongdoing by Defendants.

WHAT MIGHT HAPPEN IF THERE WERE NO SETTLEMENT?

33. If there were no Settlement and Class Representative did not obtain a reversal of the District Court's Order Granting Defendants' Motion for Summary Judgment on its pending appeal, then neither Class Representative nor the other Class Members would recover anything from Defendants. Likewise, if the appeal was successful, but Class Representative failed to establish any essential legal or factual element of its claims against Defendants at trial, Class Members would recover nothing from Defendants. Also, if Defendants were successful in proving any of their defenses, either at trial or on a subsequent appeal, the Class could recover less than the amount provided in the Settlement, or nothing at all.

HOW ARE CLASS MEMBERS AFFECTED BY THE ACTION AND THE SETTLEMENT?

34. As a Class Member, you are represented by Class Representative and Class Counsel, unless you enter an appearance through counsel of your own choice at your own expense. You are not required to retain your own counsel, but if you choose to do so, such counsel must file a notice of appearance on your behalf and must serve copies of his or her appearance on the attorneys listed in the section entitled, "When And Where Will The Court Decide Whether To Approve The Settlement?," on page 13 below.

35. If you are a Class Member and you wish to object to the Settlement, the Plan of Allocation, or Class Counsel's application for attorneys' fees and Litigation Expenses, you may present your objections by following the instructions in the section entitled, "When And Where Will The Court Decide Whether To Approve The Settlement?," on page 13 below.

36. If you are a Class Member, you will be bound by any orders issued by the Court. If the Settlement is approved, the Court will enter a judgment (the "Judgment"). The Judgment will dismiss with prejudice the claims against Defendants and will provide that, upon the Effective Date of the Settlement, Class Representative and each of the other Class Members, on behalf of themselves, and their respective heirs, executors, administrators, predecessors, successors, assigns, parents, affiliates, representatives, attorneys, and agents, in their capacities as such, shall be deemed to have, and by operation of law and of the Judgment or the Alternate Judgment, if applicable, shall have fully, finally, and forever compromised, settled, released, resolved, relinquished, waived, and discharged each and every Released Plaintiff's Claim (as defined in ¶ 37 below) against Defendants and the other Defendants' Releasees (as defined in ¶ 38 below), and shall forever be barred and enjoined from prosecuting any or all of the Released Plaintiff's Claims directly or indirectly against any of the Defendants and the other Defendants' Releasees.

37. "Released Plaintiff's Claims" means all claims (including "Unknown Claims" as defined in ¶ 39), disputes, demands, losses, liabilities, rights, damages, losses, actions or causes of action, obligations, sums of money due, judgments, suits, amounts, matters, issues and charges of any kind whatsoever (including, but not limited to, any claims for interest, attorneys' fees, expert or consulting fees, and any other costs, expenses, amounts, or liabilities whatsoever) of every nature and description whatsoever, whether in law or in equity, that have been or could have been asserted in the Action or could in the future be asserted in any forum, whether foreign or domestic, whether arising under federal, state, common, or foreign law, by Class Representative, any member of the Class, or their respective successors, assigns, parents, affiliates, executors, administrators, representatives, attorneys, and agents, in their capacities as such, whether brought directly or indirectly against any of the Defendants' Releasees, that (a) arise out of, are based on, or relate in any way to any of the allegations, claims, disclosures, acts, transactions, facts, events, circumstances, matters, occurrences, conduct, failures to act, statements, representations or omissions involved, set forth, alleged or referred to in the Action (or any complaint filed in the Action) or which could have been alleged or referred to in the Action, and (b) arise out of, are based on, or relate to the purchase or acquisition of ChemoCentryx common stock during the Class Period. "Released Plaintiff's Claims" does not, however, include (i) any claims to enforce the settlement; or (ii) any claims of any person or entity who or which is excluded from the Class.

38. “Defendants’ Releasees” means (i) Defendants, (ii) each of their respective past, present and future Immediate Family Members (for individuals) and each of their direct or indirect parent entities, subsidiaries, related entities and affiliates, any trust of which Defendant Thomas J. Schall is the settler or which is for the benefit of any Defendant and/or member(s) of his or his family, (iii) Amgen, Inc., and (iv) for any of the entities included in (i), (ii) or (iii), their respective past, present and future general partners, limited partners, principals, shareholders, joint venturers, parent entities, subsidiaries, related entities and affiliates, members, officers, directors, managers, managing directors, supervisors, employees, contractors, consultants, experts, auditors, accountants, financial advisors, professional advisors, investment bankers, representatives, insurers, trustees, trustors, agents, attorneys (including Defendants’ counsel and all other counsel who have represented any current or former Defendant in the Action), professionals, parents, predecessors, successors, assigns, heirs, executors, administrators, estates, beneficiaries, foundations and any controlling person thereof, in their capacities as such, and any entity in which a Defendant has a controlling interest.

39. “Unknown Claims” means any and all Released Plaintiff’s Claims against the Defendants’ Releasees that Class Representative, Class Counsel, or any Class Member does not know or suspect to exist in his, her, their, or its favor at the time of their release, and any and all Released Defendants’ Claims against the Plaintiff’s Releasees that any Defendant does not know or suspect to exist in his, her, their, or its favor at the time of their release, including without limitation those that, if known might have affected in any way his, her, their, or its decision(s) with respect to the settlement or the releases. With respect to any and all Released Claims, the Parties agree that, upon the Effective Date of the Settlement, Class Representative and each Defendant shall expressly waive, and each Class Member shall be deemed to have waived, and by operation of the judgment shall have waived, any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable, or equivalent to Cal. Civ. Code §1542, which provides:

A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

Class Representative, other Class Members, and Defendants may hereafter discover facts, legal theories, or authorities in addition to or different from those which any of them now knows or believes to be true with respect to the subject matter of the Released Claims, but Class Representative, each Class Member, and Defendants shall be deemed to have settled and released, and upon the Effective Date and by operation of the Judgment have settled and released, fully, finally, and forever, any and all Released Claims, as applicable, without regard to the subsequent discovery or existence of such different or additional facts, legal theories, or authorities. Class Representative and Defendants acknowledge, and each of the other Class Members shall be deemed by operation of law to have acknowledged, that the foregoing waiver was separately bargained for and a key element of the Settlement.

40. The Judgment will also provide that, upon the Effective Date of the Settlement, Defendants, on behalf of themselves, and their respective heirs, executors, administrators, predecessors, successors, assigns, parents, affiliates, representatives, attorneys, and agents, in their capacities as such, will have fully, finally, and forever compromised, settled, released, resolved, relinquished, waived, and discharged each and every Released Defendants’ Claim (as defined in ¶ 41 below) against Class Representative and the other Plaintiff’s Releasees (as defined in ¶ 42 below), and shall forever be barred and enjoined from prosecuting any or all of the Released Defendants’ Claims directly or indirectly against any of the Plaintiff’s Releasees.

41. “Released Defendants’ Claims” means all claims (including “Unknown Claims” as defined in ¶ 39), disputes, demands, liabilities, losses, rights, and causes of action of any nature whatsoever, obligations, sums of money due, judgments, suits, amounts, matters, issues and charges of any kind whatsoever (including, but not limited to, any claims for interest, attorneys’ fees, expert or consulting fees, and any other costs, expenses, amounts, or liabilities whatsoever) of every nature and description whatsoever, whether in law or in equity, that have been or could have been asserted in the Action or could in the future be asserted in any forum, whether foreign or domestic, whether arising under federal, state, common, or foreign law, by the Defendants’ Releasees or any of them against Class Representative, members of the Class, or Class Counsel (including, but not limited to, any of its current and former partners or employees), which: (a) arise out of or relate in any way to the institution, prosecution, assertion, settlement, or resolution of the Action (except for claims to enforce the settlement) or (b) relate to conduct of, or acts undertaken by, Class Counsel during the prosecution or investigation of the Action or any claims asserted in the Action; including without limitation any claims for defamation, slander, or libel.

42. “Plaintiff’s Releasees” means (i) Lead Plaintiff and the members of the Class, and (ii) each of their respective past, present and future family members, and their respective past, present and future general partners, limited partners, principals, shareholders, joint venturers, members, officers, directors, managers, managing directors, supervisors, employees, contractors, consultants, experts, auditors, accountants, financial advisors, professional advisors, investment bankers, representatives, insurers, trustees, trustors, agents, attorneys (including Lead Counsel and all other counsel who have represented any current or former plaintiff or proposed putative class in the Action), professionals, parents, predecessors, successors, assigns, heirs, executors, administrators, estates, beneficiaries, foundations and any controlling person thereof, in their capacities as such.

HOW DO I PARTICIPATE IN THE SETTLEMENT? WHAT DO I NEED TO DO?

43. To be eligible for a payment from the Settlement, you must be a member of the Class and you must timely complete and return the Claim Form with adequate supporting documentation ***postmarked (if mailed), or submitted online at www.ChemoCentryxSecuritiesLitigation.com no later than October 1, 2026.*** You may obtain a Claim Form from the website maintained by the Claims Administrator for the case, www.ChemoCentryxSecuritiesLitigation.com. You may also request that a Claim Form be mailed to you by calling the Claims Administrator toll-free at 1-833-522-2606 or by emailing the Claims Administrator at info@ChemoCentryxSecuritiesLitigation.com. **Please retain all records of your ownership of and transactions in ChemoCentryx common stock, as they will be needed to document your Claim.** The Parties and Claims Administrator do not have information about your transactions and holdings in ChemoCentryx common stock.

44. If you do not submit a timely and valid Claim Form, you will not be eligible to share in the Net Settlement Fund.

HOW MUCH WILL MY PAYMENT BE?

45. At this time, it is not possible to make any determination as to how much any individual Class Member may receive from the Settlement.

46. Pursuant to the Settlement, Defendants have agreed to cause \$69,000,000 in cash (the “Settlement Amount”) to be paid into an escrow account. The Settlement Amount plus any interest earned thereon is referred to as the “Settlement Fund.” If the Settlement is approved by the Court and the Effective Date occurs, the “Net Settlement Fund” (that is, the Settlement Fund less (a) all federal, state and/or local taxes on any income earned by the Settlement Fund and the reasonable costs incurred in connection with determining the amount of and paying taxes owed by the Settlement Fund (including reasonable expenses of tax attorneys and accountants); (b) the reasonable costs and expenses incurred in connection with providing notices to Class Members and administering the Settlement on behalf of Class Members; (c) any

attorneys' fees and Litigation Expenses awarded by the Court; and (d) any other costs or fees approved by the Court) will be distributed to Class Members who submit valid Claim Forms, in accordance with the proposed Plan of Allocation or such other plan of allocation as the Court may approve.

47. The Net Settlement Fund will not be distributed unless and until the Court has approved the Settlement and a plan of allocation, and the time for any petition for rehearing, appeal or review, whether by certiorari or otherwise, has expired.

48. Neither Defendants nor any other person or entity that paid any portion of the Settlement Amount on their behalf are entitled to get back any portion of the Settlement Fund once the Court's order or judgment approving the Settlement becomes Final. Defendants shall not have any liability, obligation, or responsibility for the administration of the Settlement, the disbursement of the Net Settlement Fund, or the plan of allocation.

49. Approval of the Settlement is independent from approval of a plan of allocation. Any determination with respect to a plan of allocation will not affect the Settlement, if approved.

50. Unless the Court otherwise orders, any Class Member who fails to submit a Claim Form postmarked (or submitted online) on or before October 1, 2026 shall be fully and forever barred from receiving payments pursuant to the Settlement but will in all other respects remain a Class Member and be subject to the provisions of the Stipulation, including the terms of any Judgment entered and the releases given. This means that each Class Member releases the Released Plaintiff's Claims (as defined in ¶ 37 above) against the Defendants and other Defendants' Releasees (as defined in ¶ 38 above) and will be barred and enjoined from prosecuting any or all of the Released Plaintiff's Claims directly or indirectly against any of the Defendants and the other Defendants' Releasees whether or not such Class Member submits a Claim Form.

51. Participants in and beneficiaries of any employee retirement and/or benefit plan covered by ERISA ("ERISA Plan") should NOT include any information relating to shares of ChemoCentryx common stock purchased or held through the ERISA Plan in any Claim Form they submit in this Action. They should include ONLY shares of ChemoCentryx common stock purchased or held outside of an ERISA Plan. Claims based on any ERISA Plan's purchases or holdings of ChemoCentryx common stock may be made by the plan's trustees.

52. The Court has reserved jurisdiction to allow, disallow, or adjust on equitable grounds the claim of any Class Member.

53. Each Claimant shall be deemed to have submitted to the jurisdiction of the Court with respect to his, her, or its Claim Form.

54. Only Class Members or persons authorized to submit a claim on their behalf will be eligible to share in the distribution of the Net Settlement Fund. Persons and entities that are excluded from the Class by definition or that previously excluded themselves from the Class pursuant to request will not be eligible to receive a distribution from the Net Settlement Fund and should not submit Claim Forms.

55. Appendix A to this Notice sets forth the Plan of Allocation for allocating the Net Settlement Fund among Authorized Claimants, as proposed by Class Representative. At the Settlement Hearing, Class Representative will request that the Court approve the Plan of Allocation. The Court may modify the Plan of Allocation, or approve a different plan of allocation, without further notice to the Class.

**WHAT PAYMENT ARE THE ATTORNEYS FOR THE CLASS SEEKING?
HOW WILL THE LAWYERS BE PAID?**

56. Class Counsel has not received any payment for its services in pursuing claims against the Defendants on behalf of the Class, and has not been reimbursed for its out-of-pocket expenses. Before final approval of the Settlement, Class Counsel will apply to the Court for an award of attorneys' fees in an amount not to exceed 22% of the Settlement Fund. At the same time, Class Counsel also intends to apply for payment of Litigation Expenses in an amount not to exceed \$5 million.

57. Class Counsel's motion for attorneys' fees and Litigation Expenses will be filed by September 10, 2026. A copy of Class Counsel's motion will be available for review at www.ChemoCentryxSecuritiesLitigation.com. The Court will determine the amount of any award of attorneys' fees or Litigation Expenses. Such sums as may be approved by the Court will be paid from the Settlement Fund. ***Class Members are not personally liable for any such fees or expenses.***

**WHAT IF I PREVIOUSLY REQUESTED EXCLUSION FROM THE CLASS AND NOW
WANT TO BE ELIGIBLE TO RECEIVE A PAYMENT FROM THE SETTLEMENT?
HOW DO I OPT BACK INTO THE CLASS?**

58. As this Class was previously certified and Class Members had the opportunity to request exclusion from the Class in connection with class certification, the Court has exercised its discretion not to allow a second opportunity to request exclusion in connection with the Settlement proceedings.

59. However, if you previously submitted a request for exclusion from the Class in connection with the Class Notice, you may elect to opt back into the Class and be eligible to receive a payment from the Settlement. In order to opt back into the Class, you, individually or through counsel, must submit a written Request to Opt Back Into the Class addressed as follows: *ChemoCentryx Securities Litigation*, c/o Kroll Settlement Administration P.O. Box 5013 New York, NY 10150-5013. This request must be *received* no later than September 21, 2026. Your Request to Opt Back Into the Class must (a) state the name, address and telephone number of the person or entity requesting to opt back into the Class; (b) state that such person or entity "requests to opt back into the Class in *Homyk v. ChemoCentryx, Inc.*, Master File No. 4:21-cv-03343-JST" and (c) be signed by the person or entity requesting to opt back into the Class or an authorized representative. **If you opt back into the Class, you will be bound by the Judgment and the release discussed in ¶¶ 37-38 above and you will not be able to bring or continue your own litigation concerning any of the Released Plaintiff's Claims.**

60. **Please note:** Opting back into the Class in accordance with the requirements set forth above does not mean that you will automatically be entitled to receive proceeds from the Settlement. If you opt back into the Class and you wish to be eligible to participate in the distribution of proceeds from the Settlement, you are also required to submit the Claim Form and the required supporting documentation as set forth therein by no later than October 1, 2026.

**WHEN AND WHERE WILL THE COURT DECIDE WHETHER TO APPROVE THE
SETTLEMENT? DO I HAVE TO COME TO THE HEARING?
MAY I SPEAK AT THE HEARING IF I DON'T LIKE THE SETTLEMENT?**

61. **Class Members do not need to attend the Settlement Hearing. The Court will consider any submission made in accordance with the provisions below even if a Class Member does not attend the hearing. You can participate in the Settlement without attending the Settlement Hearing.**

62. **Please Note:** The date and time of the Settlement Hearing may change without further written notice to Class Members. **In order to determine whether the date and time of the Settlement Hearing have changed, it is important that you monitor the Court’s docket in the Action through the Federal Court’s Public Access to Court Electronic Records (PACER) system at <https://ecf.cand.uscourts.gov> or the Settlement website, www.ChemoCentryxSecuritiesLitigation.com, before making any plans to attend the Settlement Hearing. Any updates regarding the Settlement Hearing, including any changes to the date or time of the hearing or updates regarding in-person or remote appearances at the hearing, will be posted to the Settlement website, www.ChemoCentryxSecuritiesLitigation.com.**

63. The Settlement Hearing will be held on **October 22, 2026 at 2:00 p.m. Pacific time**, before the Honorable Jon S. Tigar of the United States District Court for the Northern District of California, by Zoom videoconference. At the Settlement Hearing, the Court will consider: (a) whether the proposed Settlement is fair, reasonable, and adequate to the Class, and should be finally approved; (b) whether a Judgment substantially in the form attached as Exhibit B to the Stipulation should be entered dismissing the Action with prejudice against Defendants; (c) whether the proposed Plan of Allocation for the proceeds of the Settlement is fair and reasonable and should be approved; (d) whether the motion by Class Counsel for attorneys’ fees and Litigation Expenses should be approved; and (e) other matters that may properly be brought before the Court in connection with the Settlement. **If you plan to attend the hearing, you should check the case website, www.ChemoCentryxSecuritiesLitigation.com, or with Class Counsel to obtain information about how to access the Settlement Hearing and to confirm that no change to the date or time of the hearing has been made.** The Court reserves the right to approve the Settlement, the Plan of Allocation, Class Counsel’s motion for attorneys’ fees and Litigation Expenses, and/or any other matter related to the Settlement at or after the Settlement Hearing without further notice to the members of the Class.

64. Any Class Member may file an objection. You may object to the proposed Settlement, the Plan of Allocation or the requested fees and expenses. If you wish to object, your objection must be made in writing and include the following: your full name, the basis for your belief that you are a member of the Class, the basis of your objection (including whether the objection applies only to the objector, to a specific subset of the Class, or to the entire Class), and your signature. You can ask the Court to deny approval of the Settlement by filing an objection. You can’t ask the Court to order a different settlement; the Court can only approve or reject the Settlement. If the Court denies approval, no settlement payments will be sent out, and the lawsuit will continue. If that is what you want to happen, you should object.

65. Any objection must be in writing. If you file a timely written objection, you may, but are not required to, appear at the Settlement Hearing, either in person or through your own attorney. If you appear through your own attorney, you are responsible for hiring and paying that attorney. All written objections and supporting papers must (a) clearly identify the case name and number *Homyk v. ChemoCentryx, Inc.*, Master File No. 4:21-cv-03343-JST; (b) be submitted to the Court either by filing them electronically, by mailing them to the Clerk of the Court, United States District Court for the Northern District of California, 1301 Clay Street, Suite 400S, Oakland, CA 94612, or by filing them in person at any location of the United States District Court for the Northern District of California; and (c) **be filed or postmarked on or before September 21, 2026.**

66. **You may not object to the Settlement, the Plan of Allocation, or Class Counsel’s motion for attorneys’ fees and Litigation Expenses if you are not a member of the Class.**

67. You may file a written objection without having to appear at the Settlement Hearing. You may not, however, appear at the Settlement Hearing to present your objection unless you first file and serve a written objection in accordance with the procedures described above, unless the Court orders otherwise.

68. If you wish to be heard orally at the hearing in opposition to the approval of the Settlement, the Plan of Allocation, or Class Counsel's motion for attorneys' fees and Litigation Expenses, and if you timely file and serve a written objection as described above, you must also file a notice of appearance with the Clerk's Office so that it is ***received on or before September 21, 2026***. Such persons may be heard orally at the discretion of the Court.

69. You are not required to hire an attorney to represent you in making written objections or in appearing at the Settlement Hearing. However, if you decide to hire an attorney, it will be at your own expense, and that attorney must file a notice of appearance with the Court so that the notice is ***received on or before September 21, 2026***.

70. The Settlement Hearing may be adjourned by the Court without further written notice to the Class, other than a posting of the adjournment on the case website, www.ChemoCentryxSecuritiesLitigation.com. If you plan to attend the Settlement Hearing, you should confirm the date and time with Class Counsel.

71. Unless the Court orders otherwise, any Class Member who does not object in the manner described above will be deemed to have waived any objection and shall be forever foreclosed from making any objection to the proposed Settlement, the proposed Plan of Allocation or Class Counsel's motion for attorneys' fees and Litigation Expenses. Class Members do not need to appear at the Settlement Hearing or take any other action to indicate their approval.

**WHAT IF I BOUGHT CHEMOCENTRYX
COMMON STOCK ON SOMEONE ELSE'S BEHALF?**

72. In connection with the previously disseminated Class Notice, Nominees were advised that, if they purchased or otherwise acquired ChemoCentryx common stock during the Class Period (from November 26, 2019 through May 6, 2021, inclusive) for the beneficial interest of persons or entities other than themselves, they must either (a) provide a list of the names, addresses, and, if available, email addresses of all such beneficial owners to Kroll Settlement Administration ("Kroll"); or (b) request from Kroll sufficient copies of the Class Notice to forward to all such beneficial owners for whom email addresses were not available, and then forward those Class Notices to all such beneficial owners.

73. If you previously provided the names and addresses of such beneficial owners identified above in connection with the Class Notice, and (i) those names and addresses remain current and (ii) you have no additional names and addresses for potential Class Members to provide to the Claims Administrator, you need do nothing further at this time. The Claims Administrator will mail the Postcard Notice of the Settlement ("Postcard Notice") to the beneficial owners whose names and addresses were previously provided in connection with the Class Notice mailing.

74. If you elected to mail or email the Class Notice directly to beneficial owners, you were advised that you must retain the mailing records for use in connection with any further notices that may be provided in the Action. If you elected this option, the Claims Administrator will forward the same number of Postcard Notices to you to send to the beneficial owners, **and you must mail and/or email the Postcard Notices to those beneficial owners by no later than seven (7) calendar days after receipt of the Settlement Notice Packets.** If you require more copies of the Postcard Notice than you previously requested in connection with the Class Notice mailing, please contact the Claims Administrator, Kroll, toll-free at 1-833-522-2606, and let them know how many notices you require.

75. If you have not already provided the names and addresses for all persons and entities on whose behalf you purchased or acquired ChemoCentryx common stock from November 26, 2019 through May 6, 2021, inclusive; or if you have additional names or updated or changed information, then the Court has ordered that you must, **WITHIN SEVEN (7) CALENDAR DAYS OF YOUR RECEIPT OF THIS SETTLEMENT NOTICE**, either: (i) send a list of the names, addresses, and, if available, email addresses of such beneficial owners to the Claims Administrator at *ChemoCentryx Securities Litigation*, c/o Kroll Settlement Administration, P.O. Box 5013, New York, NY 10150-5013, in which event the Claims Administrator shall promptly mail the Postcard Notice to such beneficial owners, or (ii) request from Kroll sufficient copies of the Postcard Notice to forward to all such beneficial owners, and mail or email the Postcard Notice to the beneficial owners within seven (7) calendar days of receipt. **As stated above, if you have already provided this information in connection with the Class Notice, unless that information has changed (e.g., beneficial owner has changed address), it is unnecessary to provide such information again.**

76. **Nominees, and their agents shall forward the Postcard Notice to (or identify names, mailing addresses, and e-mail addresses of) all beneficial owners who purchased or otherwise acquired ChemoCentryx common stock during the Class Period, regardless of whether or not those beneficial owners have enrolled in a claim-filing program with their broker or financial institution.**

77. Upon full and timely compliance with these directions, nominees may seek reimbursement of their reasonable expenses actually incurred by providing the Claims Administrator with proper documentation supporting the expenses for which reimbursement is sought. Reasonable expenses shall not exceed \$0.05 plus postage at the pre-sort rate used by the Claims Administrator per Postcard Notice mailed; \$0.05 per Postcard Notice emailed; or \$0.05 per mailing record provided to the Claims Administrator. Such properly documented expenses incurred by Nominees in compliance with these directions shall be paid from the Settlement Fund, with any disputes as to the reasonableness or documentation of expenses incurred subject to review by the Court.

CAN I SEE THE COURT FILE? WHOM SHOULD I CONTACT IF I HAVE QUESTIONS?

78. This Settlement Notice contains only a summary of the terms of the proposed Settlement. For more detailed information about the matters involved in this Action, you are referred to the papers on file in the Action, including the Stipulation, which may be reviewed by accessing the Court docket in this case through the Court's Public Access to Court Electronic Records (PACER) system at <https://ecf.cand.uscourts.gov>, or by visiting the office of the Clerk of the Court for the United States District Court for the Northern District of California, Ronald V. Dellums Federal Building & United States Courthouse, 1301 Clay Street, Suite 400S, Oakland, CA 94612, between 9:00 a.m. and 4:00 p.m., Monday through Friday, excluding Court holidays. Additionally, copies of the Stipulation and any related orders entered by the Court will be posted on the website maintained by the Claims Administrator, www.ChemoCentryxSecuritiesLitigation.com.

All inquiries concerning this Settlement Notice and the Claim Form should be directed to:

ChemoCentryx Securities Litigation
c/o Kroll Settlement Administration
P.O. Box 5013
New York, NY 10150-5013

(833) 522-2606
info@ChemoCentryxSecuritiesLitigation.com

and/or

BERNSTEIN LITOWITZ
BERGER & GROSSMANN LLP
Jonathan D. Uslander, Esq.
2121 Avenue of the Stars, Suite 2575
Los Angeles, CA 90067

(800) 380-8496
settlements@blbglaw.com

DO NOT CALL OR WRITE THE COURT, THE OFFICE OF THE CLERK OF THE COURT, DEFENDANTS OR THEIR COUNSEL REGARDING THIS NOTICE.

Dated: July 2, 2026

By Order of the Court
United States District Court
Northern District of California

APPENDIX A

PLAN OF ALLOCATION OF THE NET SETTLEMENT FUND

79. As discussed above, the Settlement provides \$69,000,000 in cash for the benefit of the Class. The Settlement Amount and any interest it earns constitute the “Settlement Fund.” The Settlement Fund, after deduction of Court-approved attorneys’ fees and Litigation Expenses, Notice and Administration Costs, Taxes, and any other fees or expenses approved by the Court, is the “Net Settlement Fund.” If the Settlement is approved by the Court, the Net Settlement Fund will be distributed to eligible Authorized Claimants, i.e., Class Members who timely submit valid Claim Forms that are accepted for payment by the Court, in accordance with a plan of allocation to be adopted by the Court. Class Members who do not timely submit valid Claim Forms will not share in the Net Settlement Fund, but will otherwise be bound by the Settlement.

80. The Plan of Allocation (the “Plan”) set forth herein is the plan that is being proposed to the Court for approval by Lead Plaintiff after consultation with its damages experts. The Court may approve the Plan with or without modification, or approve another plan of allocation, without further notice to the Class. Any Orders regarding a modification to the Plan will be posted to www.ChemoCentryxSecuritiesLitigation.com. Defendants have had, and will have, no involvement or responsibility for the terms or application of the Plan.

81. The objective of the Plan of Allocation is to equitably distribute the Net Settlement Fund among Authorized Claimants who suffered economic losses as a proximate result of the wrongdoing alleged in the Action. The calculations made pursuant to the Plan of Allocation are not intended to be estimates of, nor indicative of, the amounts that Class Members might have been able to recover after a trial. Nor are the calculations pursuant to the Plan of Allocation intended to be estimates of the amounts that will be paid to Authorized Claimants pursuant to the Settlement. The computations under the Plan of Allocation are only a method to weigh the claims of Authorized Claimants against one another for the purposes of making *pro rata* allocations of the Net Settlement Fund.

82. The Plan of Allocation was developed in consultation with Lead Plaintiff's damages experts and is based generally on the calculation for Section 10(b) damages set forth in the Expert Report of Matthew D. Cain concerning damages dated September 25, 2024. The Plan reflects the assumption that Defendants' alleged false and misleading statements and material omissions proximately caused the price of ChemoCentryx common stock to be artificially inflated throughout the Class Period. In calculating the estimated artificial inflation allegedly caused by Defendants' alleged misrepresentations and omissions, Lead Plaintiff's damages expert considered price change in ChemoCentryx common stock on May 4, 2021 and May 7, 2021, in reaction to the public disclosures, adjusting for price changes attributable to market or industry factors on those days.

83. To determine the daily artificial inflation per share, the Plan utilizes the minimum of a constant-percentage inflation and a constant-dollar inflation. Specifically, for any given trading day during the Class Period, the artificial inflation is the lesser of (i) Constant-Percentage Inflation: 78.44% of ChemoCentryx's closing share price from November 26, 2019 through May 3, 2021, and 62.21% of the closing share price from May 4, 2021 through May 5, 2021; or, (ii) Constant-Dollar Inflation: A fixed amount of \$38.07 per share from November 26, 2019 through May 3, 2021, and \$17.10 per share from May 4, 2021 through May 5, 2021. The dollar amount inflation in the price of each share of ChemoCentryx common stock based on this analysis for each trading day in the Class Period is set forth in Table A below.

84. Under the Plan, Recognized Loss Amounts are based primarily on the difference in the amount of alleged artificial inflation in the prices of ChemoCentryx common stock at the time of purchase or acquisition and at the time of sale, or the difference between the actual purchase price and sale price. In order to have a Recognized Loss Amount under the Plan of Allocation, a Class Member who purchased or otherwise acquired ChemoCentryx common stock during the Class Period must have held those shares through at least the close of trading on May 3, 2021, and purchasers on May 4, 2021 or May 5, 2021 must have held those shares through at least the close of trading on May 5, 2021.²

CALCULATION OF RECOGNIZED LOSS AMOUNT

85. Based on the formula stated below, a "Recognized Loss Amount" will be calculated for each purchase or acquisition of ChemoCentryx common stock during the Class Period that is listed on the Claim Form and for which adequate documentation is provided. If a Recognized Loss Amount calculates to a negative number or zero under the formula below, that Recognized Loss Amount will be zero.³

86. For each share of ChemoCentryx common stock purchased or otherwise acquired during the Class Period (that is, the period from November 26, 2019 through May 6, 2021, inclusive), and:

- A. Sold prior to the close of trading on May 3, 2021, the Recognized Loss Amount will be \$0.00.
- B. Sold from May 4, 2021 through and including the close of trading on May 6, 2021, the Recognized Loss Amount will be ***the lesser of***: (i) the amount of artificial inflation on the purchase/acquisition date as stated in Table A below *minus* the amount of artificial inflation on the sale date as stated in Table A below; or (ii) the purchase/acquisition price minus the sale price.

² Trading in ChemoCentryx common stock was halted before the opening of trading on May 6, 2021 and did not resume until May 7, 2021, after the end of the Class Period.

³ Any transactions in ChemoCentryx common stock executed outside of regular trading hours for the U.S. financial markets shall be deemed to have occurred during the next regular trading session.

- C. Sold from May 7, 2021 through and including the close of trading on August 4, 2021, the Recognized Loss Amount will be ***the least of***: (i) the amount of artificial inflation on the purchase/acquisition date as stated in Table A below; (ii) the purchase/acquisition price minus the average closing price from May 7, 2021 through the date of sale as stated in Table B below; or (iii) the purchase/acquisition price minus the sale price.
- D. Held as of the close of trading on August 4, 2021, the Recognized Loss Amount will be ***the lesser of***: (i) the amount of artificial inflation on the purchase/acquisition date as stated in Table A below, or (ii) the purchase/acquisition price *minus* \$12.85.⁴

ADDITIONAL PROVISIONS

87. **Calculation of Claimant’s “Recognized Claim”:** A Claimant’s “Recognized Claim” will be the sum of his, her, or its Recognized Loss Amounts as calculated under ¶ 86 above.

88. **FIFO Matching:** If a Claimant made more than one purchase/acquisition or sale of ChemoCentryx common stock during the Class Period, all purchases/acquisitions and sales will be matched on a First In, First Out (“FIFO”) basis. Class Period sales will be matched first against any holdings at the beginning of the Class Period and then against purchases/acquisitions in chronological order, beginning with the earliest purchase/acquisition made during the Class Period.

89. **Purchase/Sale Prices:** For the purposes of calculations in ¶ 86 above, “purchase/acquisition price” means the actual price paid, excluding any fees, commissions, and taxes, and “sale price” means the actual amount received, not deducting any fees, commissions, and taxes.

90. **“Purchase/Acquisition/Sale” Dates:** Purchases or acquisitions and sales of ChemoCentryx common stock will be deemed to have occurred on the “contract” or “trade” date as opposed to the “settlement” or “payment” date. The receipt or grant by gift, inheritance, or operation of law of ChemoCentryx common stock during the Class Period will not be deemed a purchase, acquisition, or sale of ChemoCentryx common stock for the calculation of a Claimant’s Recognized Loss Amount, nor will the receipt or grant be deemed an assignment of any claim relating to the purchase/acquisition/sale of ChemoCentryx common stock unless (i) the donor or decedent purchased or otherwise acquired or sold such ChemoCentryx common stock during the Class Period; (ii) the instrument of gift or assignment specifically provides that it is intended to transfer such rights; and (iii) no Claim was submitted by or on behalf of the donor, on behalf of the decedent, or by anyone else with respect to such shares of ChemoCentryx common stock.

91. **Short Sales:** The date of covering a “short sale” is deemed to be the date of purchase or acquisition of the ChemoCentryx common stock. The date of a “short sale” is deemed to be the date of sale of the ChemoCentryx common stock. In accordance with the Plan of Allocation, however, the Recognized Loss Amount on “short sales” and the purchases covering “short sales” is zero.

⁴ Pursuant to Section 21D(e)(1) of the Exchange Act, “in any private action arising under this title in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated to the market.” Consistent with the requirements of the Exchange Act, Recognized Loss Amounts are reduced to an appropriate extent by taking into account the closing prices of ChemoCentryx common stock during the “90-day look-back period” from May 7, 2021 through August 4, 2021. The mean (average) closing price for ChemoCentryx common stock during this period was \$12.85.

92. In the event that a Claimant has an opening short position in ChemoCentryx common stock, the earliest purchases or acquisitions of ChemoCentryx common stock during the Class Period will be matched against such opening short position, and not be entitled to a recovery, until that short position is fully covered.

93. **Common Stock Purchased/Sold Through the Exercise of Options:** Option contracts are not securities eligible to participate in the Settlement. With respect to ChemoCentryx common stock purchased or sold through the exercise of an option, the purchase/sale date of the common stock is the exercise date of the option and the purchase/sale price is the exercise price of the option.

94. **Market Gains and Losses:** The Claims Administrator will determine if the Claimant had a “Market Gain” or a “Market Loss” with respect to his, her, or its overall transactions in ChemoCentryx common stock during the Class Period. For purposes of making this calculation, the Claims Administrator shall determine the difference between (i) the Claimant’s Total Purchase Amount⁵ and (ii) the sum of the Claimant’s Total Sales Proceeds⁶ and the Claimant’s Holding Value.⁷ If the Claimant’s Total Purchase Amount *minus* the sum of the Claimant’s Total Sales Proceeds and the Holding Value is a positive number, that number will be the Claimant’s Market Loss; if the number is a negative number or zero, that number will be the Claimant’s Market Gain.

95. If a Claimant had a Market Gain with respect to his, her, or its overall transactions in ChemoCentryx common stock during the Class Period, the value of the Claimant’s Recognized Claim will be zero, and the Claimant will in any event be bound by the Settlement. If a Claimant suffered an overall Market Loss with respect to his, her, or its overall transactions in ChemoCentryx common stock during the Class Period but that Market Loss was less than the Claimant’s Recognized Claim, then the Claimant’s Recognized Claim will be limited to the amount of the Market Loss.

96. **Determination of Distribution Amount:** The Net Settlement Fund will be distributed to Authorized Claimants on a *pro rata* basis based on the relative size of their Recognized Claims. Specifically, a “Distribution Amount” will be calculated for each Authorized Claimant, which will be the Authorized Claimant’s Recognized Claim divided by the total Recognized Claims of all Authorized Claimants, multiplied by the total amount in the Net Settlement Fund.

97. If an Authorized Claimant’s Distribution Amount calculates to less than \$10.00, no distribution will be made to that Authorized Claimant. Those funds will be included in the distribution to Authorized Claimants whose Distribution Amount is \$10.00 or more.

98. After the initial distribution of the Net Settlement Fund, the Claims Administrator will make reasonable and diligent efforts to have Authorized Claimants cash their distribution checks. To the extent any monies remain in the Net Settlement Fund six (6) months after the initial distribution, if Class Counsel, in consultation with the Claims Administrator, determines that it is cost-effective to do so, the

⁵ The “Total Purchase Amount” is the total amount the Claimant paid (excluding all fees, taxes, and commissions) for all shares of ChemoCentryx common stock purchased or acquired during Class Period.

⁶ The Claims Administrator shall match any sales of ChemoCentryx common stock during the Class Period first against the Claimant’s opening position in ChemoCentryx common stock (the proceeds of those sales will not be considered for purposes of calculating market gains or losses). The total amount received (not deducting any fees, taxes and commissions) for sales of the remaining shares of ChemoCentryx common stock sold during the Class Period is the “Total Sales Proceeds.”

⁷ The Claims Administrator shall ascribe a “Holding Value” of \$10.46 to each share of ChemoCentryx common stock purchased or acquired during the Class Period that was still held as of the close of trading on May 5, 2021.

Claims Administrator will conduct a re-distribution of the funds remaining after payment of any unpaid fees and expenses incurred in administering the Settlement, including for such re-distribution, to Authorized Claimants who have cashed their initial distributions and who would receive at least \$10.00 from such re-distribution. Additional re-distributions to Authorized Claimants who have cashed their prior checks may occur thereafter if Lead Counsel, in consultation with the Claims Administrator, determines that additional re-distributions, after the deduction of any additional fees and expenses incurred in administering the Settlement, including for such re-distributions, would be cost-effective. At such time as it is determined that the re-distribution of funds remaining in the Net Settlement Fund is not cost-effective, the remaining balance will be contributed to the Bluhm Legal Clinic Complex Civil Litigation and Investor Protection Center at the Northwestern Pritzker School of Law.

99. Payment pursuant to the Plan of Allocation, or such other plan of allocation as may be approved by the Court, will be conclusive against all Claimants. No person shall have any claim against Lead Plaintiff, Class Counsel, Lead Plaintiff's damages experts, Lead Plaintiff's consulting experts, Defendants, Defendants' Counsel, or any of the other Plaintiffs' Releasees or Defendants' Releasees, or the Claims Administrator or other agent designated by Class Counsel arising from distributions made substantially in accordance with the Stipulation, the plan of allocation approved by the Court, or further Orders of the Court. Lead Plaintiff, Defendants, and their respective counsel, and all other Defendants' Releasees, shall have no responsibility or liability whatsoever for the investment or distribution of the Settlement Fund or the Net Settlement Fund; the plan of allocation; the determination, administration, calculation, or payment of any Claim or nonperformance of the Claims Administrator; the payment or withholding of Taxes; or any losses incurred in connection therewith.

TABLE A

**Artificial Inflation in ChemoCentryx Common Stock
November 26, 2019 through May 6, 2021**

Date	Artificial Inflation Per-Share	Date	Artificial Inflation Per-Share	Date	Artificial Inflation Per-Share
November 26, 2019	\$24.10	January 28, 2020	\$32.29	March 26, 2020	\$31.30
November 27, 2019	\$23.34	January 29, 2020	\$31.96	March 27, 2020	\$30.24
November 29, 2019	\$23.79	January 30, 2020	\$32.08	March 30, 2020	\$31.06
December 2, 2019	\$22.84	January 31, 2020	\$33.27	March 31, 2020	\$31.52
December 3, 2019	\$23.03	February 3, 2020	\$35.21	April 1, 2020	\$30.26
December 4, 2019	\$22.03	February 4, 2020	\$35.50	April 2, 2020	\$31.18
December 5, 2019	\$24.35	February 5, 2020	\$36.99	April 3, 2020	\$30.56
December 6, 2019	\$24.54	February 6, 2020	\$37.49	April 6, 2020	\$34.12
December 9, 2019	\$23.24	February 7, 2020	\$37.25	April 7, 2020	\$33.41
December 10, 2019	\$24.42	February 10, 2020	\$38.07	April 8, 2020	\$33.92
December 11, 2019	\$24.48	February 11, 2020	\$38.07	April 9, 2020	\$35.29
December 12, 2019	\$26.10	February 12, 2020	\$38.07	April 13, 2020	\$36.38
December 13, 2019	\$24.64	February 13, 2020	\$38.07	April 14, 2020	\$38.07
December 16, 2019	\$26.49	February 14, 2020	\$37.65	April 15, 2020	\$36.13
December 17, 2019	\$26.72	February 18, 2020	\$38.07	April 16, 2020	\$36.74
December 18, 2019	\$26.07	February 19, 2020	\$38.07	April 17, 2020	\$38.07
December 19, 2019	\$27.16	February 20, 2020	\$38.07	April 20, 2020	\$38.07
December 20, 2019	\$28.43	February 21, 2020	\$38.07	April 21, 2020	\$37.96
December 23, 2019	\$28.32	February 24, 2020	\$36.87	April 22, 2020	\$38.07
December 24, 2019	\$29.21	February 25, 2020	\$36.37	April 23, 2020	\$38.07
December 26, 2019	\$29.29	February 26, 2020	\$36.12	April 24, 2020	\$38.07
December 27, 2019	\$28.42	February 27, 2020	\$34.65	April 27, 2020	\$38.07
December 30, 2019	\$29.81	February 28, 2020	\$35.10	April 28, 2020	\$38.07
December 31, 2019	\$31.02	March 2, 2020	\$36.49	April 29, 2020	\$38.07
January 2, 2020	\$28.58	March 3, 2020	\$36.54	April 30, 2020	\$38.07
January 3, 2020	\$28.20	March 4, 2020	\$38.07	May 1, 2020	\$38.07
January 6, 2020	\$27.27	March 5, 2020	\$38.07	May 4, 2020	\$38.07
January 7, 2020	\$27.76	March 6, 2020	\$37.12	May 5, 2020	\$38.07
January 8, 2020	\$28.86	March 9, 2020	\$34.62	May 6, 2020	\$38.07
January 9, 2020	\$30.18	March 10, 2020	\$35.91	May 7, 2020	\$38.07
January 10, 2020	\$29.97	March 11, 2020	\$32.58	May 8, 2020	\$38.07
January 13, 2020	\$28.78	March 12, 2020	\$30.66	May 11, 2020	\$38.07
January 14, 2020	\$29.74	March 13, 2020	\$34.86	May 12, 2020	\$38.07
January 15, 2020	\$29.53	March 16, 2020	\$27.01	May 13, 2020	\$38.07
January 16, 2020	\$32.10	March 17, 2020	\$27.49	May 14, 2020	\$38.07
January 17, 2020	\$34.25	March 18, 2020	\$25.67	May 15, 2020	\$38.07
January 21, 2020	\$33.51	March 19, 2020	\$27.43	May 18, 2020	\$38.07
January 22, 2020	\$33.35	March 20, 2020	\$28.89	May 19, 2020	\$38.07
January 23, 2020	\$31.96	March 23, 2020	\$29.45	May 20, 2020	\$38.07
January 24, 2020	\$32.37	March 24, 2020	\$30.81	May 21, 2020	\$38.07
January 27, 2020	\$31.86	March 25, 2020	\$30.48	May 22, 2020	\$38.07

Date	Artificial Inflation Per-Share	Date	Artificial Inflation Per-Share	Date	Artificial Inflation Per-Share
May 26, 2020	\$38.07	July 29, 2020	\$38.07	October 1, 2020	\$38.07
May 27, 2020	\$38.07	July 30, 2020	\$38.07	October 2, 2020	\$38.07
May 28, 2020	\$38.07	July 31, 2020	\$38.07	October 5, 2020	\$38.07
May 29, 2020	\$38.07	August 3, 2020	\$38.07	October 6, 2020	\$38.07
June 1, 2020	\$38.07	August 4, 2020	\$38.07	October 7, 2020	\$38.07
June 2, 2020	\$38.07	August 5, 2020	\$38.07	October 8, 2020	\$38.07
June 3, 2020	\$38.07	August 6, 2020	\$38.07	October 9, 2020	\$38.07
June 4, 2020	\$38.07	August 7, 2020	\$38.07	October 12, 2020	\$38.07
June 5, 2020	\$38.07	August 10, 2020	\$38.07	October 13, 2020	\$38.07
June 8, 2020	\$38.07	August 11, 2020	\$38.07	October 14, 2020	\$38.07
June 9, 2020	\$38.07	August 12, 2020	\$38.07	October 15, 2020	\$38.07
June 10, 2020	\$38.07	August 13, 2020	\$38.07	October 16, 2020	\$38.07
June 11, 2020	\$38.07	August 14, 2020	\$38.07	October 19, 2020	\$38.07
June 12, 2020	\$38.07	August 17, 2020	\$38.07	October 20, 2020	\$38.07
June 15, 2020	\$38.07	August 18, 2020	\$38.07	October 21, 2020	\$38.07
June 16, 2020	\$38.07	August 19, 2020	\$38.07	October 22, 2020	\$38.07
June 17, 2020	\$38.07	August 20, 2020	\$38.07	October 23, 2020	\$38.07
June 18, 2020	\$38.07	August 21, 2020	\$38.07	October 26, 2020	\$38.07
June 19, 2020	\$38.07	August 24, 2020	\$38.07	October 27, 2020	\$38.07
June 22, 2020	\$38.07	August 25, 2020	\$38.07	October 28, 2020	\$38.07
June 23, 2020	\$38.07	August 26, 2020	\$38.07	October 29, 2020	\$38.07
June 24, 2020	\$38.07	August 27, 2020	\$38.07	October 30, 2020	\$37.65
June 25, 2020	\$38.07	August 28, 2020	\$38.07	November 2, 2020	\$37.06
June 26, 2020	\$38.07	August 31, 2020	\$38.07	November 3, 2020	\$37.86
June 29, 2020	\$38.07	September 1, 2020	\$38.07	November 4, 2020	\$38.07
June 30, 2020	\$38.07	September 2, 2020	\$38.07	November 5, 2020	\$38.07
July 1, 2020	\$38.07	September 3, 2020	\$37.74	November 6, 2020	\$38.07
July 2, 2020	\$38.07	September 4, 2020	\$37.30	November 9, 2020	\$38.07
July 6, 2020	\$38.07	September 8, 2020	\$36.36	November 10, 2020	\$38.07
July 7, 2020	\$38.07	September 9, 2020	\$38.07	November 11, 2020	\$38.07
July 8, 2020	\$38.07	September 10, 2020	\$37.16	November 12, 2020	\$38.07
July 9, 2020	\$38.07	September 11, 2020	\$37.71	November 13, 2020	\$38.07
July 10, 2020	\$38.07	September 14, 2020	\$38.07	November 16, 2020	\$38.07
July 13, 2020	\$38.07	September 15, 2020	\$38.07	November 17, 2020	\$38.07
July 14, 2020	\$38.07	September 16, 2020	\$38.07	November 18, 2020	\$38.07
July 15, 2020	\$38.07	September 17, 2020	\$38.07	November 19, 2020	\$38.07
July 16, 2020	\$38.07	September 18, 2020	\$38.07	November 20, 2020	\$38.07
July 17, 2020	\$38.07	September 21, 2020	\$38.07	November 23, 2020	\$38.07
July 20, 2020	\$38.07	September 22, 2020	\$38.07	November 24, 2020	\$38.07
July 21, 2020	\$38.07	September 23, 2020	\$38.07	November 25, 2020	\$38.07
July 22, 2020	\$38.07	September 24, 2020	\$38.07	November 27, 2020	\$38.07
July 23, 2020	\$38.07	September 25, 2020	\$38.07	November 30, 2020	\$38.07
July 24, 2020	\$38.07	September 28, 2020	\$38.07	December 1, 2020	\$38.07
July 27, 2020	\$38.07	September 29, 2020	\$38.07	December 2, 2020	\$38.07
July 28, 2020	\$38.07	September 30, 2020	\$38.07	December 3, 2020	\$38.07

Date	Artificial Inflation Per-Share	Date	Artificial Inflation Per-Share	Date	Artificial Inflation Per-Share
December 4, 2020	\$38.07	February 10, 2021	\$38.07	April 16, 2021	\$36.50
December 7, 2020	\$38.07	February 11, 2021	\$38.07	April 19, 2021	\$35.14
December 8, 2020	\$38.07	February 12, 2021	\$38.07	April 20, 2021	\$35.52
December 9, 2020	\$38.07	February 16, 2021	\$38.07	April 21, 2021	\$36.42
December 10, 2020	\$38.07	February 17, 2021	\$38.07	April 22, 2021	\$36.29
December 11, 2020	\$38.07	February 18, 2021	\$38.07	April 23, 2021	\$36.00
December 14, 2020	\$38.07	February 19, 2021	\$38.07	April 26, 2021	\$37.15
December 15, 2020	\$38.07	February 22, 2021	\$38.07	April 27, 2021	\$36.05
December 16, 2020	\$38.07	February 23, 2021	\$38.07	April 28, 2021	\$36.08
December 17, 2020	\$38.07	February 24, 2021	\$38.07	April 29, 2021	\$35.30
December 18, 2020	\$38.07	February 25, 2021	\$38.07	April 30, 2021	\$37.91
December 21, 2020	\$38.07	February 26, 2021	\$38.07	May 3, 2021	\$38.07
December 22, 2020	\$38.07	March 1, 2021	\$38.07	May 4, 2021	\$16.57
December 23, 2020	\$38.07	March 2, 2021	\$38.07	May 5, 2021	\$17.10
December 24, 2020	\$38.07	March 3, 2021	\$38.07	May 6, 2021 ⁸	\$0.00
December 28, 2020	\$38.07	March 4, 2021	\$38.07		
December 29, 2020	\$38.07	March 5, 2021	\$38.07		
December 30, 2020	\$38.07	March 8, 2021	\$38.07		
December 31, 2020	\$38.07	March 9, 2021	\$38.07		
January 4, 2021	\$38.07	March 10, 2021	\$38.07		
January 5, 2021	\$38.07	March 11, 2021	\$38.07		
January 6, 2021	\$38.07	March 12, 2021	\$38.07		
January 7, 2021	\$38.07	March 15, 2021	\$38.07		
January 8, 2021	\$38.07	March 16, 2021	\$38.07		
January 11, 2021	\$38.07	March 17, 2021	\$38.07		
January 12, 2021	\$38.07	March 18, 2021	\$38.07		
January 13, 2021	\$38.07	March 19, 2021	\$38.07		
January 14, 2021	\$38.07	March 22, 2021	\$38.07		
January 15, 2021	\$38.07	March 23, 2021	\$38.07		
January 19, 2021	\$38.07	March 24, 2021	\$38.07		
January 20, 2021	\$38.07	March 25, 2021	\$38.07		
January 21, 2021	\$38.07	March 26, 2021	\$38.07		
January 22, 2021	\$38.07	March 29, 2021	\$38.07		
January 25, 2021	\$38.07	March 30, 2021	\$38.07		
January 26, 2021	\$38.07	March 31, 2021	\$38.07		
January 27, 2021	\$38.07	April 1, 2021	\$38.07		
January 28, 2021	\$38.07	April 5, 2021	\$38.07		
January 29, 2021	\$38.07	April 6, 2021	\$38.07		
February 1, 2021	\$38.07	April 7, 2021	\$37.65		
February 2, 2021	\$38.07	April 8, 2021	\$38.07		
February 3, 2021	\$38.07	April 9, 2021	\$38.07		
February 4, 2021	\$38.07	April 12, 2021	\$36.32		
February 5, 2021	\$38.07	April 13, 2021	\$37.01		
February 8, 2021	\$38.07	April 14, 2021	\$37.13		
February 9, 2021	\$38.07	April 15, 2021	\$36.98		

8. Trading in ChemoCentryx common stock was halted before the opening of trading on May 6, 2021 and did not resume until May 7, 2021.

TABLE B

90-Day Look-back Table for ChemoCentryx Common Stock
Closing Price and Average Closing Price
May 7, 2021 through August 4, 2021

Date	Closing Price	Average Closing Price from May 7, 2021 through Date Shown		Date	Closing Price	Average Closing Price from May 7, 2021 through Date Shown
May 7, 2021	\$10.46	\$10.46		June 22, 2021	\$12.89	\$10.98
May 10, 2021	\$10.97	\$10.72		June 23, 2021	\$12.76	\$11.04
May 11, 2021	\$10.75	\$10.73		June 24, 2021	\$13.06	\$11.10
May 12, 2021	\$10.05	\$10.56		June 25, 2021	\$13.77	\$11.17
May 13, 2021	\$9.97	\$10.44		June 28, 2021	\$14.29	\$11.26
May 14, 2021	\$10.44	\$10.44		June 29, 2021	\$14.09	\$11.34
May 17, 2021	\$9.89	\$10.36		June 30, 2021	\$13.39	\$11.39
May 18, 2021	\$10.36	\$10.36		July 1, 2021	\$13.20	\$11.44
May 19, 2021	\$9.96	\$10.32		July 2, 2021	\$13.18	\$11.48
May 20, 2021	\$10.06	\$10.29		July 6, 2021	\$14.05	\$11.54
May 21, 2021	\$9.59	\$10.23		July 7, 2021	\$14.47	\$11.61
May 24, 2021	\$9.81	\$10.19		July 8, 2021	\$15.10	\$11.69
May 25, 2021	\$9.67	\$10.15		July 9, 2021	\$16.77	\$11.81
May 26, 2021	\$9.77	\$10.13		July 12, 2021	\$17.34	\$11.93
May 27, 2021	\$10.41	\$10.14		July 13, 2021	\$16.29	\$12.03
May 28, 2021	\$10.15	\$10.14		July 14, 2021	\$15.72	\$12.10
June 1, 2021	\$10.16	\$10.15		July 15, 2021	\$15.49	\$12.18
June 2, 2021	\$10.20	\$10.15		July 16, 2021	\$15.85	\$12.25
June 3, 2021	\$9.98	\$10.14		July 19, 2021	\$15.63	\$12.32
June 4, 2021	\$10.03	\$10.13		July 20, 2021	\$16.12	\$12.39
June 7, 2021	\$10.72	\$10.16		July 21, 2021	\$15.83	\$12.46
June 8, 2021	\$10.94	\$10.20		July 22, 2021	\$14.99	\$12.51
June 9, 2021	\$11.18	\$10.24		July 23, 2021	\$14.37	\$12.54
June 10, 2021	\$11.54	\$10.29		July 26, 2021	\$14.54	\$12.58
June 11, 2021	\$12.18	\$10.37		July 27, 2021	\$14.66	\$12.61
June 14, 2021	\$13.17	\$10.48		July 28, 2021	\$15.51	\$12.67
June 15, 2021	\$12.81	\$10.56		July 29, 2021	\$14.97	\$12.71
June 16, 2021	\$13.24	\$10.66		July 30, 2021	\$14.78	\$12.74
June 17, 2021	\$13.53	\$10.76		August 2, 2021	\$14.89	\$12.78
June 18, 2021	\$13.51	\$10.85		August 3, 2021	\$15.11	\$12.81
June 21, 2021	\$13.06	\$10.92		August 4, 2021	\$15.32	\$12.85